111 related articles for article (PubMed ID: 29877745)
21. Acute hyperinsulinemia decreases plasma osteoprotegerin with diminished effect in type 2 diabetes and obesity.
Jørgensen GM; Vind B; Nybo M; Rasmussen LM; Højlund K
Eur J Endocrinol; 2009 Jul; 161(1):95-101. PubMed ID: 19380455
[TBL] [Abstract][Full Text] [Related]
22. Effects of Sweet Cherry Polyphenols on Enhanced Osteoclastogenesis Associated With Childhood Obesity.
Corbo F; Brunetti G; Crupi P; Bortolotti S; Storlino G; Piacente L; Carocci A; Catalano A; Milani G; Colaianni G; Colucci S; Grano M; Franchini C; Clodoveo ML; D'Amato G; Faienza MF
Front Immunol; 2019; 10():1001. PubMed ID: 31130968
[TBL] [Abstract][Full Text] [Related]
23. The relationship between serum FGF-23 concentration and insulin resistance, prediabetes and dyslipidemia in obese children and adolescents.
Kutluturk Y; Akinci A; Ozerol IH; Yologlu S
J Pediatr Endocrinol Metab; 2019 Jul; 32(7):707-714. PubMed ID: 31211688
[TBL] [Abstract][Full Text] [Related]
24. Osteoprotegerin and RANKL serum levels and their relationship with serum ghrelin in children with chronic renal failure and on dialysis.
Ozkaya O; Buyan N; Bideci A; Gonen S; Ortac E; Fidan K; Cinaz P; Söylemezoğlu O
Nephron Clin Pract; 2007; 105(4):c153-8. PubMed ID: 17259742
[TBL] [Abstract][Full Text] [Related]
25. Effect of Resistance Exercise on Serum Osteoprotegerin Levels and Insulin Resistance in Middle-Aged Women with Metabolic Syndrome.
Hur S; Cho SH; Song BK; Cho BJ
Med Sci Monit; 2018 Dec; 24():9385-9391. PubMed ID: 30582576
[TBL] [Abstract][Full Text] [Related]
26. Osteoprotegerin, Receptor Activator of Nuclear Factor Kappa B Ligand, and Growth Hormone/Insulin-Like Growth Factor-1 Axis in Children with Growth Hormone Deficiency.
Witkowska-Sędek E; Rumińska M; Stelmaszczyk-Emmel A; Sobol M; Demkow U; Pyrżak B
Adv Exp Med Biol; 2018; 1116():63-73. PubMed ID: 30284692
[TBL] [Abstract][Full Text] [Related]
27. Selected adipose tissue hormones, bone metabolism, osteoprotegerin and receptor activator of nuclear factor-kB ligand in postmenopausal obese women.
Ostrowska Z; Świętochowska E; Marek B; Kajdaniuk D; Tyrpień-Golder K; Wołkowska-Pokrywa K; Damasiewicz-Bodzek A; Kos-Kudła B
Endokrynol Pol; 2014; 65(6):438-48. PubMed ID: 25554611
[TBL] [Abstract][Full Text] [Related]
28. Plasma levels of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in patients with neuroblastoma.
Granchi D; Garaventa A; Amato I; Paolucci P; Baldini N
Int J Cancer; 2006 Jul; 119(1):146-51. PubMed ID: 16450378
[TBL] [Abstract][Full Text] [Related]
29. Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis.
Reyes-García R; Muñoz-Torres M; García DF; Mezquita-Raya P; García Salcedo JA; de Dios Luna J
Menopause; 2010; 17(1):140-4. PubMed ID: 19574937
[TBL] [Abstract][Full Text] [Related]
30. Associations between OPG and RANKL polymorphisms, vertebral fractures, and abdominal aortic calcification in community-dwelling older subjects: the Sao Paulo Ageing & Health Study (SPAH).
Pereira RMR; Figueiredo CP; Cha CC; Caparbo VF; Oliveira RM; Franco AS; Menezes PR; de Castro I; Onuchic LF
Osteoporos Int; 2016 Nov; 27(11):3319-3329. PubMed ID: 27311721
[TBL] [Abstract][Full Text] [Related]
31. [The relationships between changes of serum osteoprotegerin, nuclear factor-kappa B ligand receptor activator, and age, menopause, bone biochemical markers and bone mineral densities in women aged 20 - 75].
Liu JM; Zhao HY; Ning G; Zhao YJ; Chen Y; Zhang LZ; Xu MY; Chen JL
Zhonghua Nei Ke Za Zhi; 2004 Jun; 43(6):447-50. PubMed ID: 15312444
[TBL] [Abstract][Full Text] [Related]
32. Osteoprotegerin and osteoprotegerin/TRAIL ratio are associated with cardiovascular dysfunction and mortality among patients with renal failure.
Kuźniewski M; Fedak D; Dumnicka P; Stępień E; Kuśnierz-Cabala B; Cwynar M; Sułowicz W
Adv Med Sci; 2016 Sep; 61(2):269-275. PubMed ID: 27128817
[TBL] [Abstract][Full Text] [Related]
33. Osteoprotegerin/RANKL system imbalance in active polyarticular-onset juvenile idiopathic arthritis: a bone damage biomarker?
Spelling P; Bonfá E; Caparbo VF; Pereira RM
Scand J Rheumatol; 2008; 37(6):439-44. PubMed ID: 18802807
[TBL] [Abstract][Full Text] [Related]
34. Serum levels of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand as markers of periprosthetic osteolysis.
Granchi D; Pellacani A; Spina M; Cenni E; Savarino LM; Baldini N; Giunti A
J Bone Joint Surg Am; 2006 Jul; 88(7):1501-9. PubMed ID: 16818976
[TBL] [Abstract][Full Text] [Related]
35. Activation of the receptor activator of the nuclear factor-κB ligand pathway during coronary bypass surgery: comparison between on- and off-pump coronary artery bypass surgery procedures.
Galeone A; Brunetti G; Rotunno C; Oranger A; Colucci S; de Luca Tupputi Schinosa L; Zallone A; Grano M; Paparella D
Eur J Cardiothorac Surg; 2013 Aug; 44(2):e141-7. PubMed ID: 23671202
[TBL] [Abstract][Full Text] [Related]
36. Effect of lifestyle interventions with or without metformin therapy on serum levels of osteoprotegerin and receptor activator of nuclear factor kappa B ligand in patients with prediabetes.
Arslan MS; Tutal E; Sahin M; Karakose M; Ucan B; Ozturk G; Cakal E; Biyikli Gencturk Z; Ozbek M; Delibasi T
Endocrine; 2017 Feb; 55(2):410-415. PubMed ID: 27743302
[TBL] [Abstract][Full Text] [Related]
37. Imbalance of osteoprotegerin/receptor activator of nuclear factor-κB ligand and oxidative stress in patients with obstructive sleep apnea-hypopnea syndrome.
Ma XR; Wang Y; Sun YC
Chin Med J (Engl); 2019 Jan; 132(1):25-29. PubMed ID: 30628956
[TBL] [Abstract][Full Text] [Related]
38. Osteoprotegerin expression and serum values in obese women with type 2 diabetes mellitus.
Rashad NM; El-Shal AS; Shalaby SM; Abdel-Nour HM; Sarhan WM
Mol Biol Rep; 2021 Nov; 48(11):7095-7104. PubMed ID: 34487291
[TBL] [Abstract][Full Text] [Related]
39. Relationship between circulating serum osteoprotegerin and total receptor activator of nuclear κ-B ligand levels, triglycerides, and coronary calcification in postmenopausal women.
Poornima IG; Mackey RH; Buhari AM; Cauley JA; Matthews KA; Kuller LH
Menopause; 2014 Jul; 21(7):702-10. PubMed ID: 24473535
[TBL] [Abstract][Full Text] [Related]
40. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.
Alvarez L; Peris P; Guañabens N; Vidal S; Ros I; Pons F; Filella X; Monegal A; Muñoz-Gomez J; Ballesta AM
Arthritis Rheum; 2003 Mar; 48(3):824-8. PubMed ID: 12632438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
